NOVO-B:CPH
Նովո Նորդիսկ
259,60 DKK
arrow_downward
-1,46%(-3,85) 1D
16 հոկ, 17:00:00 GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOVO-B...
Open
261,00 DKK
High
262,15 DKK
Low
259,35 DKK
Mkt. cap
880,08 մլրդ
Avg. vol.
5,23 մլն
Volume
0,00
52-wk high
409,95 DKK
52-wk low
224,25 DKK
Shares outstanding
3,39 մլրդ
No. of employees
67 հզր
Open
261,00 DKK
High
262,15 DKK
Low
259,35 DKK
Mkt. cap
880,08 մլրդ
Avg. vol.
5,23 մլն
Volume
0,00
52-wk high
409,95 DKK
52-wk low
224,25 DKK
Shares outstanding
3,39 մլրդ
No. of employees
67 հզր
News stories
From web sources and news partners
Simply Wall Street
·
35 րոպե առաջ
Novo Nordisk (NVO) Stock May Be Undervalued As Buybacks Continue
ad-hoc-news.de
·
11 ժամ առաջ
Novo-Nordisk stock heads into the next Xetra session at EUR 34.48
The Motley Fool
·
1 օր առաջ
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
Yahoo Finance
·
1 օր առաջ
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Նովո Նորդիսկ
CEOMaziar Mike Doustdar
Employees66,7 հզր
Founded1923
HeadquartersBagsværd, Մայրաքաղաքային տարածաշրջան, Դանիա
Sector-
Websitenovonordisk.com